New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
06:09 EDTSGYPSynergy Pharmaceuticals to start second phase 3 clinical trial for plecanatide
Synergy Pharmaceuticals announced the start of its second pivotal phase 3 clinical trial to confirm the safety and efficacy of plecanatide, its lead uroguanylin analog and once-daily oral treatment, in adult patients with chronic idiopathic constipation, or CIC. This phase 3 trial is a randomized, double-blind clinical trial to compare a 12-week, dose-ranging regimen of plecanatide against placebo in adult patients with CIC.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
10:25 EDTSGYPOptions with decreasing implied volatility
Subscribe for More Information
November 16, 2015
16:53 EDTSGYPPaulson reduced stake in Valeant
Paulson & Co. gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: Perrigo (PRGO), CIT Group (CIT), Precision Castparts (PCP), Cameron (CAM), and Altera (ALTR). INCREASED STAKES: Teva (TEVA), Post Holdings (POST), Starwood Hotels (HOT), LivaNova (LIVN), and Synergy Pharmaceuticals (SGYP). DECREASED STAKES: Valeant (VRX), Shire (SHPG), Whiting Petroleum (WLL), Computer Sciences (CSC), and Oasis Petroleum (OAS). LIQUIDATED STAKES: Houghton Mifflin Harcourt (HMHC), Broadcom (BRCM), and Sprint (S).
06:01 EDTSGYPSynergy Pharmaceuticals appoints Gary Sender as CFO
Subscribe for More Information
November 12, 2015
08:02 EDTSGYPSynergy Pharmaceuticals still a saleable asset, says Canaccord
Canaccord still views Synergy Pharmaceuticals (SGYP) as a saleable asset, with Valeant (VRX) or Shire (SHPG) seen as the most obvious buyers. The firm also sees the cost of the launch of plecanatide as lower than expected and sees no need for the company to raise capital until at least the end of 2016. Canaccord reiterated its Buy rating and $19 price target on Synergy Pharmaceuticals shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use